Abstract Angiogenesis has not been extensively studied in Parkinson's disease (PD) despite being associated with other neurodegenerative disorders. Post-mortem human brain tissues were obtained from subjects with pathologically confirmed Parkinson's disease (PD) and progressive supranuclear palsy (PSP), a rapidly progressing Parkinsonian-like disorder. Tissues were also obtained from subjects with incidental Lewy body disease (iLBD) who had Lewy bodies in the substantia nigra pars compacta (SN pc ) but had not been diagnosed with PD, and age-matched controls without Lewy body pathology. The SNpc, putamen, locus ceruleus (LC) and midfrontal cortex were examined for integrin avb3, a marker for angiogenesis, along with vessel number and activated microglia. All parkinsonian syndromes had greater avb3 in the LC and the SN pc , while only PD and PSP subjects had elevated avb3 in the putamen compared to controls. PD and PSP subjects also had increases in microglia number and activation in the SN pc suggesting a link between inflammation and clinical disease. Microglia activation in iLBD subjects was limited to the LC, an area involved at an early stage of PD. Likewise, iLBD subjects did not differ from controls in avb3 staining in the putamen, a late area of involvement in PD. The presence of avb3 reactive vessels in PD and its syndromes is indicative of newly created vessels that have not likely developed the restrictive properties of the blood brain barrier. Such angiogenic vessels could contribute to neuroinflammation by failing to protect the parenchyma from peripheral immune cells and inflammatory or toxic factors in the peripheral circulation.
Introduction
Parkinson's disease (PD) is a progressive neuroinflammatory disease characterized by slowness of movement, rigidity, postural instability, and resting tremor (Fahn and Przedborski 2000) . These clinical manifestations of disease result from a marked loss of dopamine (DA) neurons in the substantia nigra pars compacta (SN pc ) and reduced projections to the caudate and putamen (striatum) as well as neurodegenerative changes in other brain regions including the locus ceruleus (LC). Degenerating neurons contain Lewy Bodies, a histological hallmark of PD composed of cytoplasmic inclusions containing a-synuclein and other aggregated proteins. PD patients also have increased numbers of activated microglia in disease-afflicted areas indicating neuroinflammation (Croisier et al. 2005; McGeer and McGeer 2008; McGeer et al. 1988; Whitton 2007; Zhang et al. 2005) . Upon activation, microglia release pro-inflammatory cytokines including tumor necrosis factor-alpha (TNFa), interleukin (IL)-1b and transforming growth factor-b (Whitton 2007) that are thought to participate in DA neuron death.
Many of the cytokines released by activated microglia in PD are not only pro-inflammatory, but also pro-angiogenic (Naldini and Carraro 2005; Pogue and Lukiw 2004) . Likewise the pro-angiogenic molecule, Vascular Endothelial Growth Factor (VEGF) is elevated in the SN pc of PD patients (Wada et al. 2006; Yasuda et al. 2007) . It is, therefore, not surprising that Faucheux and colleagues showed an increase in the number of stained nuclei of endothelial cells in the SN of PD patients consistent with an increase in vessel density, but the increase in endothelial cell nuclei was not observed in the ventral tegmental area, an area not affected in PD (Faucheux et al. 1999 ). In addition, Barcia et al. (2005) observed increased numbers of blood vessels in close proximity to degenerating DA neurons in the SN of non-human primates, which correlated with increased VEGF expression. Taken together, these data suggest that angiogenic changes may accompany the pathophysiological processes underlying PD.
Angiogenesis may also be associated with blood brain barrier (BBB) dysfunction (Barcia et al. 2004 ). In the periphery, newly created angiogenic vessels are leaky due to their numerous fenestrea, widened inter-endothelial junctions, abnormal endothelial cell shape, and discontinuous or absent basement membrane (Baluk et al. 2004 ). In the brain, immature vessels likely lack the full characteristics of the BBB, including the development of tight junctions, recruitment of pericytes, and the formation of a glial limitans. Thus, angiogenesis may compromise the BBB, which could contribute to ongoing neuroinflammation by allowing peripheral molecules and immune cells access to brain parenchyma. Indeed, we and others have shown that the BBB is dysfunctional in a variety of animal models of PD resulting in punctate leakage of FITClabeled albumin (FITC-LA) and other tracers (Carvey et al. 2005; Carvey et al. 2009; Chen et al. 2008; Westin et al. 2006) . Our group as well as others also demonstrated increased entry of drugs (Carta et al. 2006; Carvey et al. 2005; Westin et al. 2006) as well as the peripheral immune cells (Benner et al. 2008; Brochard et al. 2009; Reynolds et al. 2010) in the animal models of PD suggesting alterations in barrier integrity. Interestingly, the punctate areas of FITC-LA leakage present in the SN and striatum of a toxin-induced animal model of PD co-localized with the angiogenic marker (b3 integrin) indicating an association between angiogenesis and BBB dysfunction (Carvey et al. 2005) . Therefore, expression of integrins could be used to assess angiogenesis and possible BBB integrity in patients.
To assess angiogenic vessels in PD autopsy material, we used integrin avb3 as an angiogenic marker. avb3 is not expressed on patent vessels, but is dramatically increased on angiogenic vessels (Brooks et al. 1994a, b; Brooks 1996; Folkman 2004; Friedlander et al. 1995) . Indeed, antibodies to either the b3 subunit or to the avb3 heterodimer have been used to measure angiogenesis in a variety of conditions including abdominal aneurysm, ovarian cancer, retinopathy, myocardial infarction, and cortical stroke (Kalinowski et al. 2008; Lahdenranta et al. 2007; Paik et al. 2004; Wei et al. 2001; Willmann et al. 2008) . In this study, we used an antibody to the avb3 heterodimer that we have previously used to identify angiogenic vessels in postmortem tissues from human subjects with Alzheimer's disease (AD) (Desai et al. 2009 ). In an effort to determine if angiogenesis was present early in the disease process, we also assessed angiogenesis in tissues from subjects with incidental Lewy Body disease (iLBD). Although there remains some controversy concerning the staging of PD by Lewy Body pathology (Kalaitzakis et al. 2008; Braak and Del Tredici 2008) , iLBD is thought to represent pre-clinical PD, as these subjects have Lewy Bodies upon autopsy but lack clinical symptoms of PD Dickson et al. 2008) . We also examined autopsy tissue from subjects with Progressive Supranuclear Palsy (PSP), a more rapidly progressing parkinsonian disorder with atypical clinical features including vertical gaze and pseudobulbar palsy (Steele et al. 1964) . PSP is marked by significant neuronal degeneration, protein aggregates in affected brain regions, and neuroinflammation (Ishizawa and Dickson 2001) . By examining a range of Parkinsonian disorders, we demonstrate that angiogenesis is not only present in PD patients, but also in iLBD and PSP suggesting that angiogenic changes are an element of the neurodegenerative process.
Materials and methods

Human subjects
Deceased and autopsied subjects were from the Rush Alzheimer's disease center including the Religious Orders Study and the Clinical Cores (Bennett et al. 2006b ). The Religious Orders Study and Clinical Cores are longitudinal clinical-pathological studies of aging and AD (Bennett et al. 2006a) . Participants of the Religious Orders Study are older Catholic nuns, priests, or brothers from the Chicago area and about 40 additional sites throughout the country who enroll without known dementia and agree to brain donation at the time of death. Participants of the Religious Orders Study and Clinical Core have annual clinical evaluations, which includes medical history, neurological examination, neuropsychological performance testing and diagnostic classification. All Religious Orders Study subjects sign an Anatomical Gift Act donating his/her brain to Rush investigators at the time of death. The next of kin for the clinic patients and clinical core participants sign autopsy consents at the time of death. The Institutional Review Board of Rush University Medical Center approved all the procurement procedures for tissues used in this study.
Group criteria
Nine PD cases, six iLBD, four PSP and ten control cases were evaluated (Table I ). Prior to our receiving the tissues, all cases were evaluated for the presence of Lewy bodies in 6-lm sections from the SNpc using a-synuclein immunohistochemistry (Schneider et al. 2007 (Schneider et al. , 2009a Wilson et al. 2010) . PD subjects had moderate to severe neuronal loss in the SN pc , Lewy Bodies in the SN pc and were clinically diagnosed with PD. iLBD cases were identified as having Lewy Bodies in the SN pc upon autopsy and were not clinically diagnosed with PD. None of the iLBD cases had neocortical Lewy Bodies. PSP subjects fulfilled standard criteria for pathologic diagnosis including degeneration in multiple brain regions with neurofibrillary tangles and neuropil threads in the basal ganglia and brain stem (Hauw et al. 1994) . One PSP subject also had Lewy bodies in the substantia nigra. Any drug regimen taken by the subjects was noted during annual examination. Age-matched control cases were selected based on lack of neurofibrillary tangles and Lewy Bodies in the substantia nigra. A board-certified neuropathologist blindly reviewed all sections for diagnosis and provided sections for this study in a blinded fashion.
Post-mortem brain tissue processing
Brains of deceased subjects were removed in a standard fashion, weighed, cut into 1 cm-thick coronal slabs, digitally photographed, fixed, and stored (Bennett et al. 2006a ). The location, age, and volume of all macroscopic infarctions were recorded. Tissues were fixed for at least 72 h in 4% paraformaldehyde and stored in cryoprotectant. The following regions were dissected into 0.5-cm-thick blocks and embedded in paraffin, cut at 40 lm, and used for integrin avb3 and microglia immunohistochemistry: one hemisection of substantia nigra pars compacta (area 9) at the level caudal to the exit of the 3rd nerve (region of the decussation of the superior cerebellar peduncles), one hemisection of the mid to upper midbrain including locus ceruleus, one section of putamen immediately posterior to the anterior commissure, and for the mid frontal cortex, Brodman area 9/46, middle frontal gyrus.
Immunohistochemistry
In general, seven to eight sections for each brain region for each subject were available. Alternating sections were used for the microglia studies and for the avb3 studies. Sections underwent antigen unmasking and were incubated with primary antibody overnight. An antibody that recognizes an epitope present when the av and b3 integrin subunits are associated (Clone BV3; 1:100; Abcam; Cambridge, MA) was used to label endothelial cells undergoing angiogenesis. This antibody is specific for the avb3 integrin heterodimer and does not recognize other b3 or av heterodimers. We have previously used this antibody to verify that angiogenesis was associated with Alzheimer's disease and found that staining was limited to vessels in the brain (Desai et al. 2009 ).
Activated microglia were identified using an antibody against MHC Class II molecule located on the cell surface (HLA-DR, -DQ, -DP, Clone Cr3/43, 1:100, Dako, Glostrup, Denmark). Immunostaining was performed using the avidin-biotin-peroxidase method (ABC Elite; Vector, Burlingame, CA) with 3,3 diaminobenzidine (DAB) as the chromagen for integrin avb3, and activated microglia.
Assessment of avb3
Integrin avb3 immunoreactivity was visualized using a Leitz Fluovert FU microscope (Leitz; Wetzlar, Germany) in the SN pc , putamen, locus ceruleus and midfrontal cortex. Within each region, 100% of the delineated tissue section was scanned for vessels in a 4 9 5 mm counting frame at 259 magnification. Previous studies indicated that vessels had a range of staining (Desai et al. 2009 ). Rather than rely on an arbitrary decision as to what constituted an angiogenic vessel, or institute a semi-quantitative scale for rating positive vessels, an optical density protocol was used (Desai et al. 2009 ). Pictures of the areas within the sections were taken using brightfield microscopy and the images were opened in NIH image J (Image J 1.36b; National Institutes of Health, Bethesda, MD). All Longitudinal blood vessels evident in brightfield microscopy were identified. Vessels perpendicular to the section (cross-sectional vessels) were often stained, but were not counted to avoid any false positives due to edge effects around potential holes in the tissue. All longitudinal vessels were traced using the free-hand tracing tools available in NIH Image J and the integrated optical density was determined for the area constrained by the vessel tracing. The tracing of the vessel was moved to an area of the section free of vessels and pigmented cells, and the optical density of that area was taken as a background. The background density was subtracted from the vessel density. The vessel densities were averaged for all the vessels within a section and then across the 3-4 sections for each brain region for a given subject.
Vessels were counted in the same images used above for the avb3 optical density measurements. As with optical density determinations, only longitudinal vessels, regardless of length, were counted. Each ramification was counted as an individual vessel. Vessels were counted in the entire tissue section on a 2D plane of the saved jpeg image. Since vessels were not counted within the thickness of the tissue, a volume measurement could not be assessed. However, this method reduces the possibility of counting cross-sectional, tortuous or non-continuous vessels multiple times through the thickness of the section. In order to determine the vessel number, the number of vessels was summed across three or four sections for each patient in each brain region. The total number of vessels was divided by the total area evaluated for vessels to yield a measure of vessel number/mm 2 . Because the same sections were used for vessel counts and avb3 density measurements, counterstaining the sections for vessels would have interfered with the avb3 density measurements. Vessels were identifiable by the morphology of vessels (longitudinal) and absence of cells within the lumen. However, the sensitivity of the vessel measurements is likely limited to larger microvessels with a visible lumen while smaller capillaries may have been undetected.
Microglia immunohistochemistry and assessment
Microglia cell counts were assessed in the same brain regions used for integrin avb3 immunohistochemistry. An Olympus BX60 microscope with a computer-controlled motorized stage, high sensitivity HV-C20 CCD video camera (Hitachi, Japan) and StereoInvestigator software version 5.1 (MicroBrightField, Colchester, VT) was used to estimate microglia cell counts and volume of the sampling region in equidistant serial sections. Activated microglia were determined by MHC Class II immunoreactivity and by the more compact phagocytic morphology characteristic of activated microglia, stage C and D as identified in Kanaan et al. (Kanaan et al. 2008) . The number of activated microglia was counted within the thickness of the tissue section under an Olympus 1009 objective using the unbiased three-dimensional counting adapted from Gunderson (Williams and Rakic 1988) . The areas of interest were delineated at low power magnification prior to random sampling. The mean surface area was: 12,822,748 lm 2 for the SN pc , 820,146 lm 2 for the LC, 36,981,880 lm 2 for the putamen and 17,094,003 lm 2 for the mid frontal cortex. Approximately 10-20% of the region was quantified using a 200 9 200 lm counting frame. Due to the limited number of human post-mortem brain tissue sections, between three to four sections were available for each subject. Therefore, the total number of activated microglia and the volume of tissue evaluated was divided to obtain a density measurement. Density of activated microglia was expressed as total number/mm 3 .
Statistics
Before preceding with ANOVA to analyze the avb3, vessel count, microglia, age at death and PMI data, a Bartlett statistic and a Kolmogorov and Smirnov test were used to determine if the data had equal standard deviations (SD) and a Gaussian distribution required by ANOVA. Demographics were compared using ANOVA. PMI required the use of a non-parametric Kruskal-Wallis test.
In the case of the avb3 integrated densities and vessel numbers, a log transformation was applied and the Bartlett test confirmed equal SD and the Kolmogorov and Smirnov test confirmed a Gaussian distribution. One-Way ANOVA was used to determine within group and between group variations for each brain area. If the one-way ANOVA was significant, a Dunnett Multiple Comparison Test was used post hoc to determine if PD, iLBD, and PSP differed from control.
Results
Demographics
The mean age at death was 81.9 ± 2.9 years for controls. PD cases were of a similar age as controls while iLBD, and PSP cases were slightly older (Table 1) albeit not significantly different from control subjects (F (3,25) = 0.62, p = 0.61; Table 1 ). The average PMI for the patient groups was 6.2 h and for controls was 11.4 h. PMI was higher in controls, most likely to due to two patients with PMIs [20 h. However, there were no significant differences in PMI across the groups (H = 2.85, p = 0.42). None of the Control or iLBD subjects had a clinical diagnosis of PD. Inclusion of the PD and PSP cases for this study was primarily based on the pathologic diagnosis. The PD cases also required a final clinical diagnosis of Parkinson's disease. For PD subjects, the average duration of significant clinical signs of PD was 5 ± 1 years with a range of 1-10 years before death. Data on the duration of the diagnosis were present for eight of the nine PD subjects. Age at death 81.9 ± 2.9 84.0 ± 3.4 81.1 ± 2.2 87.6 ± 4.9
Post mortem interval (h)
11.4 ± 3.5 5.1 ± 1 7.3 ± 1. In order to determine whether vessels were actively undergoing angiogenesis, we assessed integrin avb3 immunoreactivity, an adhesion molecule present on endothelial cells of angiogenic vessels (Brooks 1996) (Fig. 1 ). Significant changes in avb3 immunoreactivity were present in the SN pc (F (3,19) = 5.67, p \ 0.01) , putamen (F (3,16) = 6.07, p \ 0.01), and locus ceruleus (F (3,19) = 5.73, p \ 0.01), but not midfrontal cortex (F (3,17) = 0.82, p = 0.49) (Fig. 2) . Not all subjects had sufficient tissues in each brain region and this is reflected in the degrees of freedom. All the significant differences were then subjected to post hoc analyses using Dunnett's multiple comparison tests to determine which groups differed from control. In the SN pc , PD (p \ 0.01), iLBD (p \ 0.05) and PSP (p \ 0.05) exhibited increased avb3 immunoreactivity relative to age-matched controls (Fig. 2) . In the putamen both PD (p \ 0.05) and PSP (p \ 0.01) exhibited significantly greater avb3 immunoreactivity than controls. iLBD subjects showed an intermediate level of enhanced avb3 reactivity in the putamen, but it did not reach statistical significance (Fig. 2) . In the LC, PD (p \ 0.05), iLBD (p \ 0.05) and PSP (p \ 0.01) had significantly more avb3 immunoreactivity than controls (Fig. 2) . Although avb3 immunoreactivity was not significantly altered in the midfrontal cortex, it is interesting to note that PSP patients exhibited a marked increase in immunoreactivity. Taken together, these results indicate that angiogenesis as measured by avb3 reactivity was ongoing in all three Parkinsonian disorders, but there were differences in the localization of avb3 reactivity. Although angiogenesis is a dynamic process and vessels may develop or regress, the numbers of vessels in each brain region was counted to determine if prior angiogenic activity resulted in an increased number of vessels. Although vessel number appeared to increase in all brain areas (Fig. 3) , only changes in the SN pc (F (3,19) = 3.22, p \ 0.05) and MFC (F (3,17) = 5.66, p \ 0.01) were statistically significant. Dunnett's multiple comparison tests indicated that only the PSP subjects had a greater number of vessels than controls in both the SN pc (p \ 0.05) and in the MFC (p \ 0.01). Although there was evidence of increased vessel number in the LC in all three Parkinsonian conditions (Fig. 3) , the overall data did not reach significance (F (3,19) = 2.72, p = 0.07).
Activated microglia
To assess the degree of neuroinflammation in each group, the number of activated microglia cells, identified by MHC Class II immunoreactivity, was determined in each brain region using stereology. Activated microglia were identified using a scale established previously (Kanaan et al. 2008) . The number of activated microglia was significantly different in the SN pc (F (3,17) (Fig. 5) . These changes were disease specific as PD (p \ 0.01) and PSP (p \ 0.05) had more activated microglia in the SN pc while iLBD did not differ from control (Fig. 5) . In the LC, only the preclinical iLBD cases had more activated microglia than controls (p \ 0.05) (Fig. 5) . In the MFC, only the PSP subjects had a significant increase in microglia (p \ 0.05) (Fig. 5) .
Discussion
Angiogenesis has been observed in a variety of neurodegenerative diseases and their animal models including Alzheimer's disease (AD) (Desai et al. 2009; Pogue and Lukiw 2004; Schultheiss et al. 2006; Thirumangalakudi et al. 2006; Vagnucci and Li 2003) , and multiple sclerosis (MS) (Holley et al. 2010; Kirk et al. 2004; Roscoe et al. 2009 ). Angiogenesis has also been observed in animal models of PD (Barcia 2005) and both increases in endothelial cell counts (Faucheux et al. 1999 ) and the presence of angiogenic factors (Wada et al. 2006; Yasuda et al. 2007 ) are consistent with its presence in human PD. The data presented indicate that angiogenesis, as measured by avb3 reactivity, is present in human PD. Integrin avb3 reactivity was present (Fig. 2) in the disease-affected areas (Braak et al. 2004 ), but was sparse in the MFC, an area not significantly involved in PD. Likewise, avb3 positive vessels were present in iLBD suggesting that it may appear in the preclinical period of PD. Unlike PD and PSP subjects, iLBD subjects had an intermediate level of angiogenesis that was not statistically different from controls in the putamen, an area affected in the later stages of PD. In addition, angiogenesis does not appear dependent on microglia activation, as angiogenesis was present in the SN pc of iLBD without microglia activation. In PD, angiogenesis may not have progressed to new vessel formation, as increases in vessel number/mm 2 were not observed, but the methods used may not have been sensitive enough to detect all such microvascular changes. The more rapidly progressing PSP subjects also had wide spread angiogenesis and areas of higher vessel number/mm 2 were detected. Changes in angiogenesis and microglia and vessel number/ mm 2 varied with the disorder and brain region and are discussed within the context of the Braak staging of PD progression (Braak et al. 2004) . Although there were some findings that were surprising, much of the data were consistent with the idea that angiogenesis is an event that Endothelial cells of human post-mortem brain tissue were labeled with mouse anti-human integrin avb3 antibody and visualized with the chromagen DAB. Integrin avb3 reactive vessels are shown in post-mortem tissues from non-pathological controls, incidental Lewy Body Disease (iLBD), Parkinson's disease (PD) and progressive supranuclear palsy (PSP) subjects. Note the distinct pattern of staining along vessels. In most of the cases, only a small portion of the longitudinal vessel is stained. In other cases, the vessels are perpendicular resulting in a ring of staining. The grey cells seen in the SNpc are neuromelanin-containing cells that are evident in unstained tissues and could be distinguished from the avb3 staining by stain color (in the original color images), and by morphology. Black scale bars = 100 lm accompanies the neurodegenerative changes associated with Parkinsonian disorders.
avb3 reactivity was used as a marker for angiogenesis as it is absent on patent vessels and expressed on angiogenic endothelial cells undergoing cell division and migration (Brooks et al. 1994a, b; Brooks 1996; Folkman 2004; Friedlander et al. 1995) . The interpretation of angiogenesis also rests on the specificity of avb3 reactivity for angiogenic vessels, and not spurious epitopes present on other cells in the brain. Although integrins mediate cell attachment to the matrix, and a variety of integrin receptors are present in the brain, the b3 integrin does not appear to be expressed in the brain (Pinkstaff et al. 1999) . Further, a b3 monoclonal antibody does not react with autopsy brain tissue (Akiyama et al. 1991) . Despite these findings, integrin avb3 expression was reported on cultured oligodendrocyte precursor cells, but it was absent on the day of isolation and only present after 2-10 days in culture (Milner et al. 1997 ). Because avb3 is commonly upregulated in cultured cells (Horton 1990) , its expression was, likely, a response to tissue culture. The absence of b3 in brain tissue rules out the expression of the avb3 heterodimer. However, this does not mean that other related molecules are not present. For example, the av subunit is expressed in the brain in conjunction with b5 and was localized to activated microglia that express avb5 but not avb3 (Milner and Campbell 2003) . Several researchers have used a b3 integrin antibody to identify angiogenesis in animal models (Baluk and McDonald 2008; Carvey et al. 2005; Schultheiss et al. 2006 ). More specific antibodies that recognize an epitope present only when the av and b3 integrin subunits are associated, identify angiogenesis in human tissues (Baluk and McDonald 2008) . In this study, and another (Desai et al. 2009 ), we have found that an antibody that recognizes the avb3 shared epitope results in staining that is limited to vessels in brain autopsy tissue.
Subjects with PD had greater reactivity to the avb3 antibody in areas associated with PD pathology including the LC, SN pc , and putamen when compared with control subjects (Fig. 2) . In addition to increases in angiogenesis, PD subjects also had greater numbers of activated microglia when compared with controls in the SN pc (Figs. 4, 5) confirming the findings of multiple investigators (Croisier et al. 2005; McGeer and McGeer 2008; McGeer et al. 1988; Whitton 2007; Zhang et al. 2005) .
To determine if angiogenesis was present early in the disease process, we examined tissues from subjects with iLBD. These subjects had Lewy bodies, a histo-pathological hallmark of PD, but did not have clinical symptoms Dickson et al. 2008) . The distribution of Lewy Bodies in iLBD mimics that of PD in the lower brainstem and anterior olfactory nucleus and this distribution reflects the staging system of PD progression proposed by Braak (Braak and Del Tredici 2009; Braak and Del Tredici 2010; Braak et al. 2003; Braak et al. 2004 ). Although there is some controversy concerning the Braak staging in PD (Kalaitzakis et al. 2008; Braak and Del Tredici 2008) , the similarities between Lewy Body expression in PD and iLBD and the evidence that there is intermediate DA neuron loss in the SN of iLBD patients has led to the suggestion that iLBD may represent preclinical PD Dickson et al. 2008) . The avb3 and microglia data in the present study are consistent with the idea that iLBD represents a preclinical PD progression. Thus, iLBD subjects had significant increases in avb3 in the Fig. 3 Vessel number in post-mortem human tissue samples. Vessel numbers were counted under bright field microscopy as described in ''Materials and methods''. PSP subjects had increased vessel number/ mm 2 in the SN pc and MFC. iLBD subjects had a small but significant increase in vessel number/mm 2 in the MFC. Vessel number/mm 2 appeared increased in the LC for all Parkinsonian disorders but did not reach statistical significance. Data were expressed as Mean ± SEM. Statistical significance was determined using ANOVA with Dunnett test for mean comparison to control with asterisk (p \ 0.05) and double asterisk (p \ 0.01)
Evidence for angiogenesis in PD, iLBD, and PSP 65 LC and SN pc when compared to controls, but unlike PD subjects, they did not differ from control subjects in the putamen. These findings are consistent with Braak staging of PD as the LC is involved in stage 2, while the SNpc involvement begins later in stage 3 and then progresses until there is nearly complete dopamine loss in the putamen producing motor symptoms in stage 4 (Braak et al. 2004) . Unlike PD subjects, iLBD subjects did not have significant increases in activated microglia in the SNpc suggesting less neuroinflammation. Thus, compared to PD patients, the iLBD subjects had fewer activated microglia in the SNpc and less avb3 staining in the putamen, suggesting less dysfunction in the areas involved later in the disease process. Interestingly, PD patients did not exhibit increased microglia in the LC whereas iLBD subjects did (Figs. 4, 5) . While we did not observe increased microglial staining in the LC of PD subjects, others have observed a weak microglial proliferation in the LC of PD subjects (Bertrand et al. 1997) . It is possible that the lack of immunostaining for microglia in the LC of PD patients (Fig. 4) is because Fig. 4 a Microglia in the SNpc and LC. Activated microglia were labeled using an antibody to MHC class II antigen and visualized with the chromagen DAB. In the SNpc, the control and iLBD conditions have neuromelanin-containing cells but no microglia. The black scale bar = 100 lm. Microglia are evident in the PD and PSP conditions of the SNpc. Higher magnification panels are placed to the side and show microglia morphology. White scale bars are 20 lm. Note that PD shows fewer of the granular neuromelanin containing cells.
With PSP the number of neuromelanin cells obscures some of the microglia, but microglia can be seen in the higher magnification panel. In the LC, only the iLBD condition was positive for activated microglia. b Microglia in the Putamen and MFC. Activated microglia were labeled using an antibody to MHC class II antigen and visualized with the chromagen DAB. In the Putamen, no activated microglia were detected. In the MFC, only PSP subjects had activated microglia, these were evident under both low power, black scale bar = 100 lm, and high power magnification, white scale bars are 20 lm the microglia lost MHC Class II immunoreactivity, underwent apoptosis (Streit 2006) or migrated to the SNpc as part of disease progression. However, we cannot rule out the possibility that iLBD has a distinct pathology from PD. To determine if angiogenesis was a feature of a rapidly progressing Parkinsonian disorder, angiogenesis was also evaluated in autopsy materials from subjects with PSP. PSP subjects have motor deficits similar to PD subjects, and are often initially diagnosed with PD (Josephs and Dickson 2003; Rajput et al. 1991) . PSP is a distinct disorder with differing pathology and more rapid progression (Armstrong et al. 2007 ). Like PD, there was an increase in both avb3 and microglia reactivity in the SN pc (Figs. 4, 5) . Thus, both PD and PSP had activated microglia in the SN pc , but the preclinical subjects with Lewy bodies had avb3 without activated microglia in this area. In PSP patients, there were also changes in angiogenesis and microglia in the MFC that were not observed in PD patients. Although avb3 was elevated in the MFC but not significantly different from controls, PSP subjects had an increase in vessel number/ Fig. 4 continued Evidence for angiogenesis in PD, iLBD, and PSP 67 mm 2 consistent with past angiogenesis in the MFC as well as an increase in activated microglia in an area involved in PSP, but not PD pathology. The finding of activated microglia in the SN pc and MFC is consistent with the observations of microglia activation in a previous PET imaging study of PSP subjects (Gerhard et al. 2006) . It is not known if the widespread angiogenic activity observed in the PSP subjects contributed to the multi-region degeneration and atrophy seen in PSP (Armstrong et al. 2007) .
No firm conclusions can be drawn about the relationship between angiogenesis and microglia activation. We had expected that angiogenesis would result from the inflammatory agents released by activated microglia. However, our results indicate that angiogenesis is more wide spread than activated microglia making it unlikely that angiogenesis is dependent exclusively on microglia activation. In an animal model of PD, treatment with L-DOPA can initiate angiogenesis independent of an inflammatory response (Lindgren et al. 2009 ). Thus, some of the angiogenesis found in the PD patients may be related to pharmacotherapy. However, iLBD subjects were neither diagnosed with PD nor treated with L-DOPA. Thus, it may be that angiogenesis precedes microglia activation, as the preclinical iLBD subjects were positive for angiogenesis in the SNpc without a significant increase in activated microglia. Likewise, the appearance of activated microglia occurred in areas either positive for avb3 or areas that had increased vessel number indicative of past angiogenesis. While these results suggest that angiogenesis could precede microglia activation, such suggestions are based on the assumption that both avb3 and activated microglia are static markers. However, integrin avb3 is a marker for ongoing angiogenesis and should be lost as a vessel matures (Brooks et al. 1994a, b; Brooks 1996; Folkman 2004; Friedlander et al. 1995) . Likewise, even vessel number is not static as vessels are being formed and pruned depending on the relative concentration of angiogenic and antiangiogenic factors (Baluk et al. 2004; Hanahan and Folkman 1996) . Thus, the evidence present at autopsy is a snapshot and may be insufficient to determine whether angiogenesis precedes microglia activation or vice versa.
It is interesting that PSP subjects were the only group to show an increase in vessel number in the SN pc . This may be a matter of timing since PSP is a rapidly progressing disease and angiogenesis may have occurred earlier and progressed further to allow for the creation of new vessels. However, if it is a matter of timing, then vessels should be evident in the LC owing to its early involvement in disease progression. There is some support for this as all of the Parkinsonian disorders exhibited increased vessel number/mm 2 relative to controls in the LC, but the increases in vessel number/ mm 2 were not statistically significant (Fig. 3) . It is possible that the high vessel number/mm 2 present in the aged controls may preclude significant increases via a ceiling effect. Another issue is that we may not have the sensitivity to detect subtle changes in vessel number. A limitation of this study is that we did not have additional tissues dedicated to counting vessel density. Vessels were identified in the avb3 stained images and a vessel specific stain was not used because it would interfere with the assessment of optical density of the avb3 staining. Thus, we may have missed small vessels that would have been visible if stained. Barcia et al. (2005) examined stained vessels and found an increase in vessel staining in the SN pc of MPTP treated monkeys that was attributed to microangiogenesis. Another study examined endothelial nuclei and found an increase in the SN pc of PD when compared with controls (Faucheux et al. 1999 ), a result consistent with increased vessel number, but this result would also be consistent with endothelial cell division occurring during angiogenesis.
The expression of avb3 suggests an ongoing process of angiogenesis in PD. Angiogenesis may be a positive response to injury, restoring circulation and providing necessary oxygenation and nutrients from the blood. Normally, astrocytes respond to a variety of stimuli including hypoxia by releasing VEGF (Kenneth and Rocha 2008; Schmid-Brunclik et al. 2008 ) a potent angiogenic factor. However, elevations of VEGF have been found in the SN pc and in the striatium of PD subjects (Wada et al. 2006; Yasuda et al. 2007 ). Further, Barcia (2005) found that MPTP treatment increased VEGF in the SN pc of monkeys. Newly created angiogenic vessels must undergo a period of maturation orchestrated by a sequence of pro-angiogenic factors (Jain 2003) . In addition, these vessels must also develop the characteristics of a BBB including, an increase in tight junctions, deposition of matrix proteins, recruitment of pericytes, and astroglial end feet. Thus, the presence of angiogenic vessels suggests that there are immature vessels in the brain that likely lack the highly differentiated structure of the BBB. The idea that the BBB may be dysfunctional in PD is controversial. A recent MRI study using a gadolinium tracer failed to find a breach in the BBB of MPTP-treated macaques (Astradsson et al. 2009 ). In addition, the widely used AAAD inhibitors, carbidopa and benserazide, do not appear to compromise levodopa therapy. In fact, carbidopa was developed based on its inability to cross the BBB while blocking peripheral decarboxylase (Celesia and Wanamaker 1976) . However, there is evidence that benserazide can enter the brain and affect levodopa metabolism (Jonkers et al. 2001; Shen et al. 2003) and that the enhanced entry of levodopa into the striatium is associated with dyskinesias (Carta et al. 2006; Westin et al. 2006 ). In addition, the BBB is dysfunctional in a variety of animal models of PD resulting in punctate leakage of FITC-labeled albumin and other tracers (Carvey et al. 2005; Carvey et al. 2009; Chen et al. 2008; Chung et al. 2010; Westin et al. 2006) . Using a b3 antibody, we determined that angiogenesis colocalized with areas of punctate FITC-albumin leakage indicating an association between angiogenesis and a localized BBB dysfunction (Carvey et al. 2005) .
In tumor biology, the continued exposure to angiogenic factors, such as VEGF can lead to ''pathological'' angiogenesis (Jain 2003; Nagy et al. 2008) . Such pathological vessels may lack pericytes, are continually leaky and can actually raise interstitial pressure, which then impedes the delivery of oxygen and nutrients (Jain 2005) . If VEGF expression is causing pathological angiogenesis and restricting oxygen delivery, it may be perpetuating its own release, as the expression of VEGF by astrocytes is at least in part driven by hypoxia (Kenneth and Rocha 2008; Schmid-Brunclik et al. 2008) . Such a feed forward mechanism could drive chronic angiogenesis, and result in exposure to peripheral toxins, cytokines and recruitment of immune cells. Such a mechanism may underlie the association of angiogenesis with various neurodegenerative diseases. In such a scenario, angiogenesis is a response to the precipitating lesion and should have a specific localization. In line with this supposition, we have determined that the expression of avb3 is highest in the MFC in AD subjects (Desai et al. 2009 ) while this area did not differ from control in iLBD, PD or PSP subjects (Fig. 2) .
Given the observational nature of autopsy data, we cannot determine if angiogenesis perpetuates the inflammatory response or if it is secondary to these events. Future studies in animal models are needed to determine if manipulating angiogenesis can affect BBB dysfunction, the entry of peripheral toxins or immune cells and ultimately DA neuron loss. If angiogenesis plays such a role in neuroinflammation, then interfering with angiogenesis may provide a new avenue for addressing neuroinflammation in PD and a variety of progressive neurological disorders.
